MRNA trade ideas
PARTY IS OVER "MASK ARE OFF" - CEO SELLS 90% OF MEDERNA SHARESOk so the CEO has sold 90 % of Mederna Shares - fact check that people - do your research!
I see downward trend from the heavens! You Bearish Put sters get in there and good luck
TELL ME WHAT U SEE OR IF I MISSING SOMETHING MY DUDES
THANKS
MRNA and PFE are going to crash even harder....$MRNA is currently running trials on an HIV vaccine.
Why?
Because they, as well $PFE, with the vaccines and the booster programs have now decimated people's immune systems.
$PFE at least has other products on the market, they may ultimately survive, but this could be the end of $MRNA.
People are dying of Vaccine induced AIDS.
The media and world leaders (lead by Prince Harry) are now advocating for the normalization of HIV testing.
WE WILL NOT FORGET, AND WE WILL NOT FORGIVE.
strategy for MRNA Wednesday 02/16/2022MRNA: buy above (153.00) once the opening is above the price we must wait for the resistance to break ((156.84) if it continues, it could touch the sell zone.
MRNA: bearish entry below (150.00) if it continues, it could reach the buy zone............ do not complicate your life price and volume are the two best indicators
MRNA - Target Hit! What Next? 🤔Continuation of previous thread where I called the start of this biotechnology bear market and the 1:1 ABC target as been hit.
At the time of making the previous thread the gap down made it clear that the upthrust was a B wave topping out at the typical 0.618 with overnight selling pressure coming in.
And now price has collapsed it is clear to see with long term trendline breaks and the 20 and 50WMA now as resistance that the dominant trend is now to the downside.
For this reason it is most likely that price will now continue to the 1.618 @$94. It may have a small X wave bounce to make a WXY or at may just capitulate in this area for a C wave extension.
And this is why i'm often less concerned about the exact EW count because it is the target fib that is what is important and relevant volatility to make that judgement. Just in the same way that if I invite you round for dinner I won't be overly concerned about the journey you take as long as you do turn up at some point.
I think also in favour of price reaching $94 is that it will intersect the lower trendline and probably go oversold on the weekly RSI.
From there I would imagine there will be another higher degree corrective upthrust before another leg down.
Not advice.
MRNA LONGModerna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). And recently we have seen it fall back to a very cheap price than it was back in 2 August 2021, In its current position we look to buy shares on MRNA as it is currently in a demand level.
MRNA 1/11/2022Well, as much as some don’t want to admit, Covid just isn’t as serious as it once was back in early 2020. With a 97-99.75 recovery rates, reduction of isolation days from 14 to 5 and no need of covid test after isolation. The dirty Politians have made their money off the vaccines and are cashing out and it reflects on the charts.
Daily Chart Analysis
After breaking out of continuation phase back in March 2020, MRNA went on quite the uptrend that saw price go from $25 to topping out at $497. A price increase of 1888%!
The last leg of the trend was broken end of Sept. 2021. Price then fell past 200ema and pulled back in form of Bear flag to its 50 ema. The bear flag was broken, and price fell below 200ema. This was the end of the uptrend of MRNA. Here we also saw the cross of 50 and 200 EMAs further confirming the bear market. After the breakdown from bear flag, price bounce several times but the EMAs rejected the price and the downtrend continued.
The downtrend is currently strengthening as it is now respecting and rejecting the 20 ema.
Price is currently at support area around 215.50.
Will be looking to short MRNA.
Entry: 223.50
Stoploss: 261.59
Target: trailing 50 ema or 110
Potential Double Bottom On Moderna (NASDAQ: $MRNA) 🧬Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, Metagenomi, Inc., and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd.; Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group; Aldevron, LLC; Institute for Life Changing Medicines; and AbCellera Biologics Inc. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.